Publication:
A prospective European trial comparing laparotomy, laparoscopy, robotic-assisted, and transanal total mesorectal excision procedures in high-risk patients with rectal cancer: The RESET trial

dc.contributor.coauthorRouanet, P.
dc.contributor.coauthorGuerrieri, M.
dc.contributor.coauthorLemercier, P.
dc.contributor.coauthorCotte, E.
dc.contributor.coauthorSpinelli, A.
dc.contributor.coauthorGómez-Ruiz, M.
dc.contributor.coauthorWolthuis, A.
dc.contributor.coauthorBertani, E.
dc.contributor.coauthorDubois, A.
dc.contributor.coauthorGroup, O. B. O. T. R. S.
dc.contributor.departmentSchool of Medicine
dc.contributor.kuauthorBalık, Emre
dc.contributor.kuauthorÖzoran, Emre
dc.contributor.schoolcollegeinstituteSCHOOL OF MEDICINE
dc.date.accessioned2026-07-07T08:48:33Z
dc.date.issued2026
dc.description.abstractTo compare total mesorectal excision (TME) techniques combined with sphincter-sparing procedures in high-risk patients (HRPs). Background: TME is the standard treatment for rectal cancer, but it can be challenging in HRPs. The available surgical approaches must be compared, especially in HRPs. Methods: Prospective, observational, multicenter trial to compare laparotomy (OTME), laparoscopy (LTME), robotic-assisted surgery (RTME), and transanal surgery (TaTME) in HRPs. The composite primary outcome included circumferential radial margin (CRM) >= 1 mm, TME grade II-III, and absence of Clavien-Dindo grade III-IV complications. Three propensity score analyses were performed (LTME vs RTME, RTME vs TaTME, LTME vs TaTME). Results: A total of 1078 HRPs (75% of men, median body mass index of 27 kg/m2, 50% of tumors in the lower third of the rectum) underwent surgery. The RTME and TaTME groups included patients with more advanced and lower tumors and coloanal anastomosis (P
dc.description.harvestedfromManual
dc.description.indexedbyWOS
dc.description.indexedbyScopus
dc.description.indexedbyPubMed
dc.description.publisherscopeInternational
dc.description.readpublishN/A
dc.description.sponsoredbyTubitakEuEU
dc.description.sponsorshipThe authors thank all patients for their participation. They also thank Aurore Moussion, Nabila Bouazza, and Hager Chabouni for maintaining data integrity, Sophie Gourgou for the methodological support, and Pablo Lemercier for ensuring data accuracy. The study was made possible thanks to the exceptional support of study coordinators and data managers at all participating centers, as well as the assistance of all surgeons who supported this investigation. The teams' diligent efforts have successfully kept the study on track despite all challenges encountered, particularly during the COVID-19 pandemic. The authors also thank Dr Fanny Salasc of the Montpellier Cancer Institute for providing medical writing and editorial support. They also thank Prof Jim Khan, Prof Esther Consten, and Dr Ritchie Geitenbeek for reviewing the manuscript and providing valuable feedback. The RESET trial was endorsed by the European Society of Coloproctology (ESCP), which supported RESET communication and performed the study's audits. They also thank Dr Elisabetta Andermarcher for editing the manuscript.
dc.description.sponsorshipEuropean Society of Coloproctology (ESCP)
dc.description.versionPublished Version
dc.identifier.WoSQuartileQ1
dc.identifier.doi10.1097/sla.0000000000006534
dc.identifier.eissn1528-1140
dc.identifier.embargoN/A
dc.identifier.endpage706
dc.identifier.issn0003-4932
dc.identifier.issue4
dc.identifier.pubmed39263755
dc.identifier.scopus2-s2.0-85204355500
dc.identifier.startpage697
dc.identifier.urihttp://doi.org/10.1097/sla.0000000000006534
dc.identifier.urihttps://hdl.handle.net/20.500.14288/33205
dc.identifier.volume283
dc.identifier.wos001711934100003
dc.keywordsRectal cancer
dc.keywordsTotal mesorectal excision
dc.keywordsSphincter-sparing procedure
dc.keywordsHigh-risk
dc.languageeng
dc.publisherWolters Kluwer Health
dc.relation.affiliationKoç University
dc.relation.collectionKoç University Institutional Repository
dc.relation.ispartofAnnals of Surgery
dc.relation.openaccessN/A
dc.rightsN/A
dc.rights.uriN/A
dc.subjectSurgery
dc.titleA prospective European trial comparing laparotomy, laparoscopy, robotic-assisted, and transanal total mesorectal excision procedures in high-risk patients with rectal cancer: The RESET trial
dc.typeJournal Article
dspace.entity.typePublication
relation.isOrgUnitOfPublicationd02929e1-2a70-44f0-ae17-7819f587bedd
relation.isOrgUnitOfPublication.latestForDiscoveryd02929e1-2a70-44f0-ae17-7819f587bedd
relation.isParentOrgUnitOfPublication17f2dc8e-6e54-4fa8-b5e0-d6415123a93e
relation.isParentOrgUnitOfPublication.latestForDiscovery17f2dc8e-6e54-4fa8-b5e0-d6415123a93e

Files